“Drug holiday” in DRONJ (Denosumab Related Osteonecrosis of the Jaws) patients : real benefit in surgical or non surgical therapeutic approach ?

One of the most frequent monoclonal antibodies linked to MRONJ is Denosumab. In our study, attention was focused on different therapeutic approaches considering patients treated only with Denosumab or in combination with other drugs associated with the genesis of ONJ. We considered two different clinical approaches: sites treated without surgery; sites treated with traditional surgery or Er:YAG laser (2940nm, 250mJ, 20Hz). In our study, the discontinuation of the drug was evaluated in relation to treatment outcomes.